Urinary Tract Infection Is a Clinical Diagnosis: Avoiding Overdiagnosis From Asymptomatic Bacteriuria, Contamination, and Culture-Driven Treatment in Primary Care

Introduction

UTI is one of the most familiar diagnoses in primary care, urgent care, emergency medicine, and long-term care transitions. It is also one of the most commonly overdiagnosed infectious conditions.

The problem is rarely a failure to recognize that urinary infections can be clinically important. The more frequent problem is that an abnormal urine test becomes the diagnosis even when the patient does not have a urinary tract syndrome.

Acute dysuria, urinary frequency, urgency, suprapubic discomfort, hematuria, flank pain, fever, rigors, costovertebral angle tenderness, or systemic manifestations may justify targeted evaluation and treatment. In contrast, bacteriuria or pyuria in a patient without attributable symptoms often represents asymptomatic bacteriuria, colonization, contamination, or another inflammatory process rather than symptomatic infection.

Once a urine culture has been ordered, a positive result may shift attention away from medication effects, dehydration, electrolyte or metabolic abnormalities, pulmonary infection, constipation, urinary retention, vaginal or urethral disease, neurologic illness, and other causes of nonspecific decline. This form of diagnostic anchoring can expose the patient to antibiotics while delaying recognition of the actual illness.

The practical objective is not undertreatment. Localized cystitis, pyelonephritis, systemic UTI, catheter-associated UTI, pregnancy-associated infection, prostatitis, and infections complicated by obstruction or other risk factors require appropriate recognition and management. The objective is diagnostic stewardship: order urine tests selectively, interpret results within the clinical syndrome, and prescribe antibiotics when the probability and severity of bacterial infection justify treatment.

Why Overdiagnosis Matters

UTI overdiagnosis can cause harm through several pathways.

Unnecessary antibiotic exposure can cause gastrointestinal intolerance, rash, severe hypersensitivity, drug interactions, renal or electrolyte complications, hematologic toxicity, Clostridioides difficile infection, and selection for resistant organisms. The type and magnitude of risk vary by agent, treatment duration, comorbidities, and concomitant medications.

A premature UTI diagnosis may also delay evaluation of the actual cause of illness. This is especially important in patients with delirium, falls, weakness, functional decline, or nonspecific systemic symptoms.

Finally, unnecessary urine cultures create a downstream prescribing cascade. When a culture returns after the visit, clinicians may feel pressure to respond to bacterial growth even when the original clinical presentation did not support infection.

UTI stewardship is therefore diagnostic before it is therapeutic. Selecting a narrower antibiotic is important, but avoiding a low-value culture may be the higher-yield intervention.

Definitions That Prevent Diagnostic Error

Symptomatic UTI

A symptomatic UTI is a clinical syndrome. A localized UTI, commonly described as cystitis, typically includes acute dysuria, urinary frequency, urgency, suprapubic discomfort, or hematuria without findings of systemic infection.

A systemic UTI should be considered when fever, rigors, flank pain, costovertebral angle tenderness, hemodynamic instability, or organ dysfunction suggests infection extending beyond the bladder. Pyelonephritis, prostatitis, and urosepsis fall within the systemic UTI spectrum.

The 2026 EAU guideline emphasizes localized versus systemic UTI rather than relying exclusively on the older uncomplicated-versus-complicated distinction. U.S. guidance continues to use the term complicated UTI, particularly for infections extending beyond the bladder or occurring in patients with factors that may alter treatment or increase the risk of failure. Urinary obstruction, catheterization, recent instrumentation, significant anatomic abnormalities, renal transplantation, immunocompromise, and prior resistant organisms are clinically important modifiers rather than interchangeable diagnostic criteria.

Asymptomatic bacteriuria

Asymptomatic bacteriuria is the presence of bacteria at specified quantitative counts in urine without signs or symptoms attributable to UTI. Pyuria may coexist with asymptomatic bacteriuria and does not convert colonization into symptomatic infection.

Contamination

Contamination refers to organisms introduced during specimen collection, transport, or processing rather than organisms originating from a clinically significant urinary infection. Mixed flora, several organisms without a dominant uropathogen, discordant findings, or a poorly collected specimen should generally prompt reassessment rather than automatic treatment.

True polymicrobial infection can occur, particularly in selected patients with catheters, urinary obstruction, instrumentation, or complex anatomy. The culture result must therefore be interpreted with the clinical syndrome, specimen source, and host factors.

Table 1. Terms That Commonly Lead to UTI Overdiagnosis

Term	Practical meaning	Diagnostic implication
Symptomatic UTI	Compatible localized or systemic clinical syndrome	Treat when clinical probability and severity justify therapy
Asymptomatic bacteriuria	Bacteria in urine without attributable UTI symptoms	Usually do not screen or treat
Pyuria	Leukocytes in urine	Indicates inflammation, not necessarily bacterial infection
Positive urine culture	Growth of one or more organisms	Interpret only in clinical context
Mixed flora	Frequently reflects collection contamination	Reassess; repeat only when clinically necessary
Cloudy or odorous urine	Low-specificity urine characteristic	Not a stand-alone reason to culture or treat

Guideline Consensus: When Asymptomatic Bacteriuria Should and Should Not Be Treated

Current major guidelines agree that most asymptomatic bacteriuria should not be screened for or treated. Treatment has not improved clinical outcomes in most studied populations and increases antibiotic exposure and the associated risks of adverse effects and antimicrobial resistance.

Pregnancy

Pregnancy remains the principal routine outpatient exception. ACOG recommends screening once with a urine culture at a visit early in prenatal care. Confirmed asymptomatic bacteriuria at clinically significant colony counts should be treated with a targeted regimen selected according to susceptibility, gestational age, allergy history, renal function, and obstetric safety considerations.

Evidence is insufficient to mandate repeat screening after a negative initial culture or after appropriate treatment of an initial episode. Follow-up should reflect current obstetric guidance and the individual clinical situation.

Endoscopic urologic procedures associated with mucosal trauma

Patients undergoing selected endoscopic urologic procedures associated with mucosal trauma should be screened before the procedure. When bacteriuria is present, the IDSA recommends culture-directed peri-procedural therapy rather than empiric treatment.

The intent is targeted prophylaxis around a high-risk procedure, not prolonged treatment of colonization. IDSA suggests a short course of one or two doses initiated approximately 30 to 60 minutes before the procedure.

Populations in which routine screening or treatment is not recommended

Routine screening or treatment is not recommended for healthy nonpregnant adults, older adults without attributable symptoms, long-term care residents, patients with diabetes, patients with long-term indwelling catheters, patients with spinal cord injury, or patients undergoing elective nonurologic surgery.

For kidney transplant recipients more than one month after transplantation, IDSA recommends against screening for or treating asymptomatic bacteriuria. Evidence is insufficient during the first month after transplantation, and management should be individualized with transplant-specialist input.

Evidence also remains limited in high-risk neutropenia and several other diagnostically complex populations.

Table 2. Asymptomatic Bacteriuria by Clinical Context

Clinical context	Screen or treat?	Practical note
Healthy nonpregnant adult	No	Avoid testing without attributable symptoms
Pregnancy	Yes	Screen once early; treat confirmed ASB with targeted therapy
Older adult without urinary or systemic signs	No	Evaluate other causes of delirium, falls, or decline
Diabetes	No	Bacteriuria alone does not justify antibiotics
Long-term indwelling catheter	No	Culture when compatible illness suggests infection
Spinal cord injury	No routine screening	Symptoms may be atypical; assess carefully
Elective nonurologic surgery	No	Avoid routine preoperative urine cultures
Endoscopic urologic procedure with mucosal trauma	Yes	Use culture-directed short-course peri-procedural therapy
Kidney transplant more than 1 month previously	No	First post-transplant month requires individualized specialist assessment
High-risk neutropenia	Evidence insufficient	Individualize with specialist input

Diagnostic Pitfalls in Primary Care

Pyuria is not infection

Pyuria is common in symptomatic UTI, but it is not specific for bacterial infection. Pyuria alone does not justify a culture or antimicrobial treatment.

Pyuria can accompany asymptomatic bacteriuria, catheter-associated bacteriuria, nephrolithiasis, sexually transmitted infections, urinary tuberculosis, interstitial nephritis, malignancy, vaginal or vulvar disease, and other forms of genitourinary inflammation.

The absence of pyuria lowers the probability of bacterial UTI in many non-neutropenic patients, particularly when symptoms are vague. It does not exclude infection in every population and should not replace assessment of the clinical syndrome.

A urinalysis showing leukocyte esterase or white blood cells should support a clinical hypothesis rather than create one.

Nitrites are supportive, not definitive

Nitrite positivity can support a diagnosis when symptoms are typical because some uropathogens reduce nitrate to nitrite. Nitrite testing is not sensitive for all organisms, and false-negative results occur.

Nitrite positivity in an asymptomatic patient still does not establish symptomatic UTI.

Colony counts do not replace symptoms

High colony counts can support a diagnosis when symptoms are compatible and the specimen was properly collected. They do not distinguish symptomatic infection from asymptomatic bacteriuria.

Conversely, lower colony counts may be clinically meaningful in a symptomatic patient, depending on the organism, specimen type, prior antimicrobial exposure, collection method, and clinical context.

Mixed flora usually requires reassessment

Mixed-flora results frequently suggest contamination, particularly in clean-catch specimens. The appropriate response is usually to reassess the patient’s symptoms, specimen quality, collection method, and need for repeat testing.

Treating mixed flora without a coherent UTI syndrome exposes the patient to antibiotic risk without a clearly identified therapeutic target. However, true polymicrobial infection should remain in the differential for selected patients with catheters, instrumentation, obstruction, or complex urologic anatomy.

Cloudy or malodorous urine is not a diagnosis

Cloudy, dark, discolored, or malodorous urine may reflect hydration status, diet, medications, crystalluria, vaginal contamination, colonization, or specimen handling. These findings can coexist with infection, but they should not independently prompt urine culture or antibiotics in the absence of localizing urinary symptoms or systemic signs.

Table 3. Common Diagnostic Pitfalls and Better Responses

Finding	Why it misleads	Better response
Pyuria alone	Common in ASB and catheterized patients	Determine whether a compatible syndrome is present
Nitrite-positive urine	Supports but does not prove infection	Interpret with symptoms and risk factors
Positive culture	May reflect ASB or contamination	Ask whether the patient has an attributable UTI syndrome
Mixed flora	Often collection contamination	Reassess specimen quality and repeat only when necessary
Cloudy or odorous urine	Poor specificity	Assess hydration, symptoms, and other causes
Delirium or fall plus bacteriuria	Bacteriuria may be incidental	Evaluate other causes unless urinary or systemic findings support infection

ASB = asymptomatic bacteriuria.

Older Adults: The Highest-Risk Zone for Overdiagnosis

Older adults are particularly vulnerable to UTI overdiagnosis because asymptomatic bacteriuria becomes more prevalent with age and acute illness may present nonspecifically.

In an older patient with bacteriuria and delirium or a fall, but no local genitourinary symptoms, fever, hemodynamic instability, or other systemic evidence of infection, IDSA recommends assessment for other causes and careful observation rather than antimicrobial treatment of bacteriuria. The evidence underlying this recommendation is limited, but treatment has not been shown to improve delirium or fall-related outcomes in this setting and can cause harm.

Delirium should trigger a broad assessment. Potential contributors include medication adverse effects, sedatives, anticholinergic burden, dehydration, electrolyte abnormalities, hypoxia, pain, constipation, urinary retention, sleep disruption, environmental change, neurologic disease, and infection outside the urinary tract.

Falls require assessment of orthostatic blood pressure, gait, vision, neuropathy, medications, arrhythmia, environmental hazards, and neurologic disease.

The clinical stance should remain balanced. Antibiotics should not be withheld from an older adult with a compatible infection. At the same time, UTI should not be diagnosed from bacteriuria alone.

Patients with fever, hemodynamic instability, organ dysfunction, or suspected sepsis require prompt evaluation. When no source is apparent, urine testing may be appropriate as part of a broad diagnostic assessment, but bacteriuria does not by itself establish the urinary tract as the source. Empiric therapy in undifferentiated sepsis should address the severity of illness and plausible urinary and nonurinary sources.

When to Order a Urine Culture

Urine culture is most useful when the result is likely to alter management.

Appropriate indications commonly include suspected pyelonephritis or systemic UTI, suspected complicated infection, recurrent UTI evaluation, treatment failure, pregnancy, planned endoscopic urologic procedures associated with mucosal trauma, atypical presentations, recent antimicrobial exposure, prior resistant organisms, and illness in which empiric treatment may be unreliable.

Culture is often unnecessary for classic localized cystitis in an otherwise low-risk, nonpregnant adult when the clinical presentation is typical and local susceptibility patterns and patient-specific factors support empiric therapy.

Clinicians should generally avoid urine cultures for isolated nonspecific symptoms, routine preoperative assessment before nonurologic surgery, cloudy or malodorous urine without attributable symptoms, reflex testing based on pyuria alone, or routine documentation of cure after clinical improvement in most nonpregnant patients.

Pregnancy is different. ACOG recommends culture for symptomatic cystitis during pregnancy and allows consideration of a repeat culture after treatment, although evidence is insufficient to establish a single required follow-up strategy.

Table 4. When to Culture and When to Treat

Scenario	Culture	Antibiotics
Classic localized cystitis in a low-risk nonpregnant adult	Often unnecessary	Treat when symptoms and assessment support bacterial cystitis
Atypical urinary symptoms	Usually appropriate	Depends on the assessment
Treatment failure	Yes	Tailor or revise therapy using results
Suspected pyelonephritis or systemic UTI	Yes	Do not delay appropriate therapy in a clinically ill patient
Suspected complicated UTI	Yes	Select according to severity and patient-specific risk
Asymptomatic nonpregnant adult	No	No
Pregnancy screening	Yes	Treat confirmed ASB
Endoscopic urologic procedure with mucosal trauma	Yes	Targeted peri-procedural therapy
Cloudy or odorous urine alone	No	No
Delirium or fall without urinary or systemic signs	Usually no	Usually no

Antibiotic Selection: Stewardship After Diagnosis

Once symptomatic UTI is reasonably diagnosed, antibiotic selection should reflect the syndrome. Localized cystitis is not managed in the same manner as pyelonephritis, systemic or complicated UTI, prostatitis, catheter-associated infection, or pregnancy-associated infection.

For low-risk acute cystitis, antibiotics improve clinical and microbiologic cure but also increase adverse effects compared with placebo. Claims that antibiotics uniformly prevent pyelonephritis or urosepsis should not be generalized from low-risk cystitis studies, in which serious complications are uncommon and trials have not consistently demonstrated a difference in pyelonephritis.

The urgency and expected benefit of treatment are greater in pyelonephritis, systemic infection, pregnancy-associated infection, urinary obstruction, and other high-risk presentations.

Established options for localized cystitis

Nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin, and selected beta-lactams remain commonly considered when their labeled indications, patient-specific factors, and local susceptibility patterns support use. No agent is appropriate for every patient.

Fluoroquinolones are active against many urinary pathogens but should generally be reserved for circumstances in which safer or narrower options are unsuitable. Current ciprofloxacin labeling directs clinicians to reserve it for acute uncomplicated cystitis when no alternative treatment options are available.

Newer FDA-approved oral options

Since publication of the older IDSA uncomplicated-cystitis guideline, the FDA has approved additional oral options:

• Pivmecillinam is approved for uncomplicated UTI in adult women caused by designated susceptible organisms.

• Gepotidacin is approved for uncomplicated UTI in female adults and pediatric patients 12 years or older who weigh at least 40 kg, caused by designated susceptible organisms.

• Sulopenem etzadroxil/probenecid is approved for uncomplicated UTI in adult women with limited or no alternative oral antibacterial options and is not indicated for complicated UTI.

These agents should not be treated as interchangeable or automatically preferred. Selection must account for the labeled population, causative organism, susceptibility, contraindications, interactions, adverse-effect profile, prior treatment, availability, and stewardship considerations.

Pyelonephritis and complicated UTI

For suspected pyelonephritis or complicated UTI, urine culture and susceptibility testing are more important. The 2025 IDSA guideline recommends a structured approach to empiric selection based on:

1. Severity of illness, particularly the presence or absence of sepsis

2. Patient-specific risk factors for resistant uropathogens

3. Allergies, contraindications, interactions, organ function, and other patient-specific considerations

4. A relevant local antibiogram for patients with sepsis, when available

Definitive therapy should be narrowed or otherwise optimized once culture and susceptibility results are available. Urinary obstruction and other correctable sources require prompt attention because antimicrobial therapy alone may be insufficient.

Medication Safety Considerations

Nitrofurantoin

Nitrofurantoin is indicated for selected lower urinary tract infections caused by susceptible organisms. It should not be used for pyelonephritis or perinephric abscess because it does not achieve adequate tissue concentrations for those infections.

U.S. product labeling contraindicates nitrofurantoin in anuria, oliguria, or significant renal impairment. Numerical renal thresholds vary among product labeling and clinical guidance, so prescribing should follow the applicable product information, current institutional guidance, and the patient’s renal function.

Additional contraindications include pregnancy at term, labor or imminent labor, neonates younger than one month, prior nitrofurantoin-associated cholestatic jaundice or hepatic dysfunction, and hypersensitivity.

Warnings include acute, subacute, and chronic pulmonary reactions, hepatotoxicity, peripheral neuropathy, hemolytic anemia, and C. difficile-associated diarrhea. Chronic pulmonary and hepatic toxicity are especially relevant with prolonged or repeated exposure.

Trimethoprim-sulfamethoxazole

Trimethoprim-sulfamethoxazole requires assessment for hypersensitivity to trimethoprim or sulfonamides, previous drug-induced immune thrombocytopenia, folate-deficiency megaloblastic anemia, marked hepatic damage, severe renal insufficiency when renal function cannot be monitored, age younger than two months, and concurrent dofetilide use.

Important warnings include severe cutaneous adverse reactions, hepatic injury, blood dyscrasias, renal effects, hypoglycemia, and embryofetal risk.

Hyperkalemia is particularly important in patients with renal impairment and those receiving angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, potassium supplements, or other potassium-raising therapies. Renal function, serum potassium, blood counts, and interacting medications should be assessed when clinically appropriate.

Fosfomycin

Oral fosfomycin tromethamine is indicated as a single-dose treatment for uncomplicated cystitis in adult women caused by susceptible strains of Escherichia coli or Enterococcus faecalis. It is not indicated for pyelonephritis or perinephric abscess.

Product labeling advises against repeated daily dosing for a single episode because repeated doses did not improve clinical success or microbiologic eradication and increased adverse events.

Fluoroquinolones

Fluoroquinolone labeling includes warnings for disabling and potentially irreversible adverse reactions involving tendons, peripheral nerves, and the central nervous system. Other clinically important risks include dysglycemia, QT prolongation, hepatotoxicity, C. difficile-associated diarrhea, photosensitivity, and exacerbation of myasthenia gravis.

Epidemiologic studies reported an increased rate of aortic aneurysm and dissection within two months after fluoroquinolone exposure, particularly in older adults. In patients with a known aortic aneurysm or increased susceptibility, ciprofloxacin labeling recommends reserving treatment for situations in which no alternative antibacterial treatment is available.

Fluoroquinolones may remain appropriate for selected patients with pyelonephritis or complicated UTI when the expected benefits outweigh the risks. They should not be used reflexively for localized uncomplicated cystitis when an effective, safer option is available.

Table 5. Antibiotic Safety Considerations

Agent or class	Appropriate role	Important cautions
Nitrofurantoin	Selected localized cystitis	Not for pyelonephritis; renal, pulmonary, hepatic, neuropathy, hemolysis, and term-pregnancy considerations
TMP-SMX	Selected cystitis when susceptibility supports use	Severe skin reactions, cytopenias, renal effects, hyperkalemia, pregnancy concerns, dofetilide contraindication
Fosfomycin	Single-dose uncomplicated cystitis in adult women	Not for pyelonephritis; avoid repeated daily dosing for one episode
Fluoroquinolones	Selected systemic or complicated infections when benefits justify risks	Tendon, neuropathy, CNS, myasthenia gravis, dysglycemia, QT, C. difficile, and aortic warnings
Beta-lactams	Alternatives in selected patients	Agent-specific allergy, efficacy, renal dosing, and collateral effects
Newer oral agents	Label-specific uncomplicated UTI populations	Distinct organism, population, interaction, and contraindication restrictions

Communication and Documentation

Language can either reinforce or reduce overtreatment.

“The urine is positive” implies that a disease has been established. A more accurate statement is: “The urine grew bacteria, but the patient does not have symptoms attributable to UTI.”

“No UTI” may sound dismissive when patients or caregivers are concerned. A clearer explanation is: “The findings are most consistent with asymptomatic bacteriuria. Antibiotics are unlikely to help and may cause harm.”

Documentation should make the diagnostic reasoning visible. Useful phrases include:

• “Asymptomatic bacteriuria; antibiotics not indicated.”

• “Mixed flora most consistent with contamination; repeat specimen only if clinically necessary.”

• “Pyuria without attributable urinary symptoms.”

• “Delirium evaluation ongoing; no localizing urinary symptoms or systemic signs currently supporting UTI.”

• “Abnormal culture reviewed in clinical context; no compatible UTI syndrome.”

Clear documentation can reduce callbacks, cross-cover prescribing, and treatment pressure when culture results return.

Practical Approach for Primary Care

A practical approach begins before any urine test is ordered.

First, determine whether the patient has a localized urinary syndrome or findings suggesting systemic infection. Evaluate for dysuria, frequency, urgency, suprapubic discomfort, hematuria, flank pain, fever, rigors, nausea, vomiting, costovertebral angle tenderness, hemodynamic instability, and organ dysfunction.

Second, assess for conditions that alter diagnostic or treatment decisions, including pregnancy, obstruction, catheterization, recent instrumentation, renal transplantation, immunocompromise, prior resistant organisms, recent antibiotic exposure, and significant urologic abnormalities.

Third, determine whether the patient belongs to a population in which asymptomatic bacteriuria should be screened for or treated. Pregnancy and selected endoscopic urologic procedures associated with mucosal trauma are the principal established exceptions.

Fourth, ask whether the result of a urinalysis or culture will change management. If the anticipated result will not change the diagnostic or therapeutic approach, avoid the test.

When a test has already been obtained, interpret it through the clinical syndrome. Pyuria, nitrite positivity, bacteriuria, and colony counts support diagnosis only when they fit the patient’s presentation.

When a result does not fit, reassess rather than prescribe automatically. Review the original symptoms, specimen quality, competing diagnoses, host factors, and clinical course.

Finally, close the loop. If another diagnosis better explains the presentation, the culture suggests contamination, or the patient’s course no longer supports bacterial infection, reassess the need for ongoing antibiotics. Decisions to start, continue, modify, or discontinue therapy should account for the original syndrome, illness severity, treatment already received, culture information, and patient-specific risk.

Limitations of the Evidence

Evidence is strongest for avoiding screening and treatment of asymptomatic bacteriuria in nonpregnant adults, older adults, patients with diabetes, patients with long-term catheters, and long-term care populations.

Evidence is more limited in the first month after kidney transplantation, high-risk neutropenia, spinal cord injury with atypical symptoms, frail older adults with diagnostically complex presentations, and patients with complex urologic anatomy. These groups may require individualized judgment and specialist input.

The evidence linking bacteriuria to delirium or falls without urinary or systemic findings is also limited. Current recommendations emphasize the absence of demonstrated treatment benefit and the known harms of unnecessary antibiotic exposure rather than claiming that a urinary contribution is impossible.

Diagnostic stewardship interventions are system-dependent. Reflex-culture rules, electronic health record prompts, laboratory reporting language, order-set design, collection workflows, and audit-and-feedback programs may perform differently across institutions.

The underlying principles are broadly applicable, but implementation should be adapted to the patient population, practice setting, laboratory capacity, and local resistance patterns.

Future Directions

Future progress in UTI stewardship will depend less on treating every abnormal urine result and more on improving diagnostic pathways.

Promising strategies include symptom-linked ordering, better specimen-collection workflows, selective reflex-culture protocols, diagnostic prompts, laboratory reports that identify likely contamination, delayed or selective reporting of susceptibility results, and audit-and-feedback systems.

Further research is needed in frail older adults, catheterized patients, spinal cord injury, early transplant recipients, high-risk neutropenia, recurrent nonspecific urinary symptoms, and patients with chronic lower urinary tract symptoms.

New diagnostic technologies will require evaluation against clinically meaningful outcomes. Improved test sensitivity alone will not solve overdiagnosis if colonization and contamination remain indistinguishable from clinically significant infection.

 

References

1. American College of Obstetricians and Gynecologists. (2023). Urinary tract infections in pregnant individuals: Clinical Consensus No. 4. Obstetrics & Gynecology, 142(2), 435-445. Reaffirmed 2026.

   https://doi.org/10.1097/AOG.0000000000005269. PMID: 37473414.

2. Centers for Disease Control and Prevention. (2024, March 13). Urine culture stewardship in patients without indwelling urinary catheters. Retrieved July 28, 2026, from

   https://www.cdc.gov/uti/hcp/clinical-guidance/culture-stewardship-without-catheter.html

3. Claeys, K. C., Trautner, B. W., Leekha, S., Coffey, K. C., Crnich, C. J., Diekema, D. J., Fakih, M. G., Goetz, M. B., Gupta, K., Jones, M. M., Leykum, L., Liang, S. Y., Pineles, L., Pleiss, A., Spivak, E. S., Suda, K. J., Taylor, J. M., Rhee, C., & Morgan, D. J. (2022). Optimal urine culture diagnostic stewardship practice: Results from an expert modified-Delphi procedure. Clinical Infectious Diseases, 75(3), 382-389.

   https://doi.org/10.1093/cid/ciab987. PMID: 34849637.

4. European Association of Urology. (2026). EAU guidelines on urological infections. EAU Guidelines Office, Arnhem, the Netherlands.

   https://uroweb.org/guidelines/urological-infections

5. Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by IDSA and ESCMID. Clinical Infectious Diseases, 52(5), e103-e120.

   https://doi.org/10.1093/cid/ciq257. PMID: 21292654.

6. Hansen, M. A., Valentine-King, M., Zoorob, R., Schlueter, M., Matas, J. L., Willis, S. E., Danek, L. C. K., Muldrew, K. L., Zare, M., Hudson, F., Atmar, R. L., Chou, A., Trautner, B. W., & Grigoryan, L. (2022). Prevalence and predictors of urine culture contamination in primary care: A cross-sectional study. International Journal of Nursing Studies, 134, 104325.

   https://doi.org/10.1016/j.ijnurstu.2022.104325. PMID: 35914376.

7. Henderson, J. T., Webber, E. M., & Bean, S. I. (2019). Screening for asymptomatic bacteriuria in adults: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 322(12), 1195-1205. https://doi.org/10.1001/jama.2019.10060. PMID: 31550037.

8. National Library of Medicine. (2026). DailyMed: Fosfomycin tromethamine granules for oral solution prescribing information. Retrieved July 28, 2026, from
   https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3ba67e7-aaca-e682-277a-94e20b0abad7

9. National Library of Medicine. (2026). DailyMed: Nitrofurantoin monohydrate/macrocrystals capsule prescribing information. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05f4b126-0fb9-5ee9-c89c-f229e60f84e3

10. National Library of Medicine. (2026). DailyMed: Sulfamethoxazole and trimethoprim tablet prescribing information. Retrieved July 28, 2026, from original article label and current DailyMed label

11. Nicolle, L. E., Gupta, K., Bradley, S. F., Colgan, R., DeMuri, G. P., Drekonja, D., Eckert, L. O., Geerlings, S. E., Köves, B., Hooton, T. M., Juthani-Mehta, M., Knight, S. L., Saint, S., Schaeffer, A. J., Trautner, B., Wullt, B., & Siemieniuk, R. (2019). Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 68(10), e83-e110.

    https://doi.org/10.1093/cid/ciy1121. PMID: 30895288.

12. Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., Jr., Kubik, M., Landefeld, C. S., Mangione, C. M., Pbert, L., Silverstein, M., Simon, M. A., Tseng, C. W., & Wong, J. B. (2019). Screening for asymptomatic bacteriuria in adults: US Preventive Services Task Force recommendation statement. JAMA, 322(12), 1188-1194.

    https://doi.org/10.1001/jama.2019.13069. PMID: 31550038.

13. Trautner, B. W., Cortés-Penfield, N. W., Gupta, K., Hirsch, E. B., Horstman, M., Moran, G. J., Colgan, R., O’Horo, J. C., Ashraf, M. S., Connolly, S., Drekonja, D., Grigoryan, L., Huttner, A., Lazenby, G. W., Nicolle, L., Schaeffer, A., Yawetz, S., & Lavergne, V. (2025). Clinical practice guideline by the Infectious Diseases Society of America: 2025 guideline on management and treatment of complicated urinary tract infections: Selection of antibiotic therapy for complicated UTI. Clinical Infectious Diseases. Advance online publication.

    https://doi.org/10.1093/cid/ciaf460. PMID: 41419213.

14. U.S. Food and Drug Administration. (2017). Fluoroquinolone safety labeling changes. Retrieved July 28, 2026, from

    https://www.fda.gov/files/about%20fda/published/Fluoroquinolone-Safety-Labeling-Updates-%28PDF—1.15MB%29.pdf

15. U.S. Food and Drug Administration. (2024). Cipro IV prescribing information. Retrieved July 28, 2026, from

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/
    019847Orig1s064correctedlbl.pdf

16. Zalmanovici Trestioreanu, A., Lador, A., Sauerbrun-Cutler, M. T., & Leibovici, L. (2015). Antibiotics for asymptomatic bacteriuria. Cochrane Database of Systematic Reviews, 2015(4), CD009534.

    https://doi.org/10.1002/14651858.CD009534.pub2. PMID: 25851268.

17. Falagas, M. E., Kotsantis, I. K., Vouloumanou, E. K., & Rafailidis, P. I. (2009). Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: A meta-analysis of randomized controlled trials. Journal of Infection, 58(2), 91-102.

    https://doi.org/10.1016/j.jinf.2008.12.009. PMID: 19195714.

18. U.S. Food and Drug Administration. (2024, April 24). FDA approves new treatment for uncomplicated urinary tract infections. Retrieved July 28, 2026, from

    https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections

19. National Library of Medicine. (2026). DailyMed: Blujepa, gepotidacin tablets prescribing information. Retrieved July 28, 2026, from
    https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d

20. U.S. Food and Drug Administration. (2024, October 25). FDA approves Orlynvah for uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options. Retrieved July 28, 2026, from

    https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no

21. National Library of Medicine. (2026). DailyMed: Ciprofloxacin tablets prescribing information. Retrieved July 28, 2026, from

    https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b281a5c0-5f3e-4e6f-86ac-ed7794aac64c